Factory 99% Aprepitant Powder CAS 170729-80-3 Chemical Intermediate Aprepitant

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A718
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Aprepitant
• CAS: 170729-80-3
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Aprepitant
Appearance	White Powder
CAS NO.	170729-80-3
MF	C23H21F7N4O3
Storage	Keep in a cool, dry, dark location

 

Aprepitant is a selective NK-1 receptor antagonist used to prevent nausea and vomiting, particularly in patients undergoing chemotherapy or surgery. Its primary function is to block the action of substance P at NK-1 receptors, reducing nausea and vomiting through central and peripheral effects. When used in combination with other antiemetic drugs, aprepitant can provide effective control of nausea and vomiting.

 

1. Chemotherapy-Induced Nausea and Vomiting (CINV): Aprepitant is commonly used in combination with other antiemetic drugs to prevent nausea and vomiting associated with chemotherapy, particularly in patients receiving highly emetogenic chemotherapy regimens.
2. Postoperative Nausea and Vomiting (PONV): It may also be used to prevent PONV in patients undergoing surgery, especially those with a high risk of developing nausea and vomiting after surgery.
3. Radiation Therapy-Induced Nausea and Vomiting: Aprepitant has shown potential in reducing nausea and vomiting associated with radiation therapy, although its use in this context may be less common than in chemotherapy.

1. NK-1 Receptor Antagonism: By binding to and blocking NK-1 receptors, aprepitant prevents the activation of these receptors by substance P, which is a key mediator of nausea and vomiting.
2. Central and Peripheral Effects: Aprepitant acts both centrally in the brain and peripherally in the gastrointestinal tract to inhibit the vomiting reflex. By reducing the activity of NK-1 receptors in these areas, it helps to decrease nausea and vomiting.
3. Enhanced Efficacy with Combination Therapy: When used in combination with other antiemetic drugs, such as 5-HT3 receptor antagonists and corticosteroids, aprepitant can provide enhanced efficacy in preventing nausea and vomiting associated with chemotherapy and other stimuli.